111 Capital Sells 9,679 Shares of Gilead Sciences, Inc. $GILD

Key Points

• 111 Capital has reduced its stake in Gilead Sciences by 29.7% during the second quarter, now holding 22,908 shares valued at approximately $2.54 million after selling 9,679 shares.
• Gilead Sciences' CEO, Daniel O'Day, sold 10,000 shares at an average price of $111.66, resulting in a 1.66% decrease in his holdings, which are now valued at around $66 million.
• Gilead recently paid a quarterly dividend of $0.79 per share, which reflects an annual yield of 2.8% and a payout ratio of 62.95%.

111 Capital reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 29.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,908 shares of the biopharmaceutical company's stock after selling 9,679 shares during the period. 111 Capital's holdings in Gilead Sciences were worth $2,540,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. QRG Capital Management Inc. raised its position in Gilead Sciences by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 299,587 shares of the biopharmaceutical company's stock valued at $33,215,000 after buying an additional 19,277 shares during the last quarter. Jackson Wealth Management LLC raised its position in Gilead Sciences by 15.4% in the 2nd quarter. Jackson Wealth Management LLC now owns 4,747 shares of the biopharmaceutical company's stock valued at $526,000 after buying an additional 633 shares during the last quarter. Stock Yards Bank & Trust Co. raised its position in Gilead Sciences by 1,069.8% in the 2nd quarter. Stock Yards Bank & Trust Co. now owns 25,220 shares of the biopharmaceutical company's stock valued at $2,796,000 after buying an additional 23,064 shares during the last quarter. Ascent Group LLC raised its position in Gilead Sciences by 52.7% in the 2nd quarter. Ascent Group LLC now owns 49,324 shares of the biopharmaceutical company's stock valued at $5,469,000 after buying an additional 17,016 shares during the last quarter. Finally, Ameritas Advisory Services LLC raised its position in Gilead Sciences by 12.6% in the 2nd quarter. Ameritas Advisory Services LLC now owns 5,492 shares of the biopharmaceutical company's stock valued at $609,000 after buying an additional 616 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 1.9%

Shares of GILD opened at $112.69 on Friday. The business has a 50-day moving average of $114.34 and a 200 day moving average of $109.92. Gilead Sciences, Inc. has a fifty-two week low of $83.98 and a fifty-two week high of $121.83. The firm has a market cap of $139.83 billion, a P/E ratio of 22.45, a price-to-earnings-growth ratio of 0.75 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GILD. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.